首页> 外文期刊>Cancer radiotherapie: journal de la Soci閠?fran鏰ise de radiotherapie oncologique >Advanced penile cancer with iliac lymph node involvement treated with radiation and concurrent gemcitabine
【24h】

Advanced penile cancer with iliac lymph node involvement treated with radiation and concurrent gemcitabine

机译:先进的阴茎癌与髂淋巴结参与辐射和同时吉西他滨治疗

获取原文
获取原文并翻译 | 示例
       

摘要

Penile cancer is a rare entity with only 2000 new cases a year in the United States. Even though early stage penile cancer has an excellent prognosis, patients with positive pelvic lymph nodes have an overall 5 year survival rate under 10%. There is no consensus for the management of pelvic node-positive patients, although most guidelines are in favour of pelvic lymph node dissection for patients with two or more positive nodes, followed by adjuvant chemotherapy. We describe here the case of a patient with numerous metastatic lymph nodes at diagnosis, treated with chemoradiation (66 Gy with concurrent gemcitabine) after failure of first-line chemotherapy and still alive and disease-free 7 years after diagnosis. (C) 2017 Published by Elsevier Masson SAS on behalf of Societe francaise de radiotherapie oncologique (SFRO).
机译:阴茎癌是在美国每年只有2000个新病例的罕见实体。 尽管早期的阴茎癌具有优异的预后,阳性盆腔淋巴结的患者均为10%以下的5年生存率。 骨盆节点阳性患者的管理没有共识,尽管大多数准则对于患有两种或更多个阳性节点的患者的骨盆淋巴结解剖,其次是辅助化疗。 我们在这里描述了在诊断中患有许多转移性淋巴结的患者,在一线化疗失败后用校长治疗(66倍,66Gy),诊断后7年仍然活着和无疾病。 (c)2017年由Elsevier Masson SAS发布代表Societe Francaise de Radiotherapie Oncologique(SFRO)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号